vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Essent Group Ltd. (ESNT). Click either name above to swap in a different company.
Essent Group Ltd. is the larger business by last-quarter revenue ($312.4M vs $247.1M, roughly 1.3× ANI PHARMACEUTICALS INC). Essent Group Ltd. runs the higher net margin — 49.6% vs 11.1%, a 38.5% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -0.8%). Essent Group Ltd. produced more free cash flow last quarter ($848.7M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 2.3%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Essentra PLC is a supplier of plastic and fibre products. The company operates internationally from headquarters in Kidlington, Oxfordshire. It is listed on the London Stock Exchange.
ANIP vs ESNT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $312.4M |
| Net Profit | $27.5M | $155.0M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 59.1% |
| Net Margin | 11.1% | 49.6% |
| Revenue YoY | 29.6% | -0.8% |
| Net Profit YoY | 367.5% | -7.7% |
| EPS (diluted) | $1.14 | $1.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $312.4M | ||
| Q3 25 | $227.8M | $311.8M | ||
| Q2 25 | $211.4M | $319.1M | ||
| Q1 25 | $197.1M | $317.6M | ||
| Q4 24 | $190.6M | $315.0M | ||
| Q3 24 | $148.3M | $316.6M | ||
| Q2 24 | $138.0M | $312.9M | ||
| Q1 24 | $137.4M | $298.4M |
| Q4 25 | $27.5M | $155.0M | ||
| Q3 25 | $26.6M | $164.2M | ||
| Q2 25 | $8.5M | $195.3M | ||
| Q1 25 | $15.7M | $175.4M | ||
| Q4 24 | $-10.3M | $167.9M | ||
| Q3 24 | $-24.2M | $176.2M | ||
| Q2 24 | $-2.3M | $203.6M | ||
| Q1 24 | $18.2M | $181.7M |
| Q4 25 | 14.1% | 59.1% | ||
| Q3 25 | 15.9% | 63.9% | ||
| Q2 25 | 6.6% | 72.4% | ||
| Q1 25 | 13.3% | 65.2% | ||
| Q4 24 | -2.3% | 61.9% | ||
| Q3 24 | -13.8% | 65.6% | ||
| Q2 24 | 3.7% | 76.4% | ||
| Q1 24 | 14.8% | 71.6% |
| Q4 25 | 11.1% | 49.6% | ||
| Q3 25 | 11.7% | 52.7% | ||
| Q2 25 | 4.0% | 61.2% | ||
| Q1 25 | 8.0% | 55.2% | ||
| Q4 24 | -5.4% | 53.3% | ||
| Q3 24 | -16.3% | 55.6% | ||
| Q2 24 | -1.7% | 65.1% | ||
| Q1 24 | 13.2% | 60.9% |
| Q4 25 | $1.14 | $1.61 | ||
| Q3 25 | $1.13 | $1.67 | ||
| Q2 25 | $0.36 | $1.93 | ||
| Q1 25 | $0.69 | $1.69 | ||
| Q4 24 | $-0.45 | $1.59 | ||
| Q3 24 | $-1.27 | $1.65 | ||
| Q2 24 | $-0.14 | $1.91 | ||
| Q1 24 | $0.82 | $1.70 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $5.8B |
| Total Assets | $1.4B | $7.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | — |
| Q4 25 | $540.7M | $5.8B | ||
| Q3 25 | $505.8M | $5.7B | ||
| Q2 25 | $436.8M | $5.7B | ||
| Q1 25 | $418.6M | $5.7B | ||
| Q4 24 | $403.7M | $5.6B | ||
| Q3 24 | $405.9M | $5.6B | ||
| Q2 24 | $455.8M | $5.4B | ||
| Q1 24 | $452.0M | $5.2B |
| Q4 25 | $1.4B | $7.4B | ||
| Q3 25 | $1.4B | $7.4B | ||
| Q2 25 | $1.3B | $7.2B | ||
| Q1 25 | $1.3B | $7.2B | ||
| Q4 24 | $1.3B | $7.1B | ||
| Q3 24 | $1.3B | $7.1B | ||
| Q2 24 | $920.8M | $6.7B | ||
| Q1 24 | $914.5M | $6.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $856.1M |
| Free Cash FlowOCF − Capex | $29.1M | $848.7M |
| FCF MarginFCF / Revenue | 11.8% | 271.7% |
| Capex IntensityCapex / Revenue | 0.5% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.10× | 5.52× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $1.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $856.1M | ||
| Q3 25 | $44.1M | $215.9M | ||
| Q2 25 | $75.8M | $189.5M | ||
| Q1 25 | $35.0M | $221.6M | ||
| Q4 24 | $15.9M | $861.5M | ||
| Q3 24 | $12.5M | $229.2M | ||
| Q2 24 | $17.4M | $188.7M | ||
| Q1 24 | $18.3M | $216.9M |
| Q4 25 | $29.1M | $848.7M | ||
| Q3 25 | $38.0M | $210.6M | ||
| Q2 25 | $71.8M | $188.8M | ||
| Q1 25 | $32.5M | $221.3M | ||
| Q4 24 | $13.5M | $854.8M | ||
| Q3 24 | $7.7M | $228.7M | ||
| Q2 24 | $13.0M | $187.6M | ||
| Q1 24 | $13.7M | $212.5M |
| Q4 25 | 11.8% | 271.7% | ||
| Q3 25 | 16.7% | 67.5% | ||
| Q2 25 | 34.0% | 59.2% | ||
| Q1 25 | 16.5% | 69.7% | ||
| Q4 24 | 7.1% | 271.3% | ||
| Q3 24 | 5.2% | 72.2% | ||
| Q2 24 | 9.4% | 60.0% | ||
| Q1 24 | 10.0% | 71.2% |
| Q4 25 | 0.5% | 2.4% | ||
| Q3 25 | 2.7% | 1.7% | ||
| Q2 25 | 1.9% | 0.2% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 1.3% | 2.1% | ||
| Q3 24 | 3.2% | 0.2% | ||
| Q2 24 | 3.2% | 0.3% | ||
| Q1 24 | 3.3% | 1.5% |
| Q4 25 | 1.10× | 5.52× | ||
| Q3 25 | 1.66× | 1.31× | ||
| Q2 25 | 8.87× | 0.97× | ||
| Q1 25 | 2.23× | 1.26× | ||
| Q4 24 | — | 5.13× | ||
| Q3 24 | — | 1.30× | ||
| Q2 24 | — | 0.93× | ||
| Q1 24 | 1.00× | 1.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ESNT
| Mortgage Insurance Segment | $192.4M | 62% |
| Other | $120.0M | 38% |
